Glaxosmithkline Pharmaceuticals Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹42,609 Cr
- P/E
- 40.47
- ROE
- 45.61%
- PEG
- 2.28
- Price to sales
- 10.78
- Debt to equity
- 0.01
- 52W high / low
- ₹3,106 / ₹2,103
- Sales growth (5Y)
- 5.49%
- EBITDA margin
- 34.22%
- Net profit margin
- 25.18%
- Promoter holding
- 75.00%
- Sales (last year)
- ₹3,955 Cr
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
Guidance scorecard · Q1 FY27 call
What Glaxosmithkline Pharmaceuticals Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
10–20%- GSK India targets sustained double-digit growth in coming quarters, aiming for 13-14% CAGR to achieve INR 8,000 crores revenue in 4-5 years.
- Growth drivers include innovation portfolio growing from 4% to 7% of sales, with oncology, new respiratory, and adult vaccines leading.
- General medicines remain relevant, expected to grow 8-10%.
- Oncology is a fastest-growing segment (industry growth 27% vs. 12-13% overall), providing significant uplift.
- Innovation assets like Shingrix (+65% growth), Nucala (doubling new patients treated), and Trelegy Ellipta continue strong momentum.
- New launches such as Jemperli, Zejula, Blenrep, Ojjaara, and Arexvy expected to contribute to growth.
2 more points from Glaxosmithkline Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Glaxosmithkline Pharmaceuticals Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- There is significant investment in front-loading activities such as medical oncologist speaker programs and evidence generation, which likely involve capital allocation towards marketing and scientific dissemination.
- The company is focused on building and scaling innovative portfolios like oncology, respiratory, and vaccines, implying ongoing strategic investments.
- Manufacturing capacity includes a setup in Nashik for local production of general medicines, with 20 contract manufacturers supplementing production, indicating capital investment in local manufacturing infrastructure.
2 more points from Glaxosmithkline Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Glaxosmithkline Pharmaceuticals Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
Ask what Glaxosmithkline Pharmaceuticals Ltd said on the order book →
Full Q1 FY27 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Glaxosmithkline Pharmaceuticals Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Glaxosmithkline Pharmaceuticals Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Glaxosmithkline Pharmaceuticals Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 787 | 762 | 957 | 805 | 930 | 815 | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 |
| Expenses + | 618 | 618 | 668 | 587 | 673 | 584 | 689 | 658 | 641 | 554 | 644 | 670 | 644 |
| Operating Profit | 170 | 144 | 289 | 218 | 257 | 231 | 322 | 292 | 333 | 251 | 336 | 371 | 351 |
| OPM % | 22% | 19% | 30% | 27% | 28% | 28% | 32% | 31% | 34% | 31% | 34% | 36% | 35% |
| Other Income + | 38 | 54 | 28 | -135 | 32 | 36 | 39 | 35 | 41 | 44 | 36 | 50 | 36 |
| Interest | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 |
| Depreciation | 17 | 16 | 18 | 17 | 18 | 16 | 17 | 19 | 15 | 16 | 17 | 20 | 13 |
| Profit before tax | 190 | 181 | 299 | 65 | 271 | 249 | 344 | 308 | 359 | 279 | 354 | 400 | 373 |
| Tax % | 30% | 27% | 27% | 30% | 28% | 27% | 27% | 25% | 27% | 27% | 27% | 26% | 26% |
| Net Profit + | 133 | 132 | 218 | 46 | 194 | 182 | 252 | 230 | 263 | 205 | 257 | 296 | 278 |
| EPS in Rs | 7.88 | 7.81 | 12.84 | 2.70 | 11.48 | 10.76 | 14.91 | 13.57 | 15.52 | 12.10 | 15.20 | 17.45 | 16.40 |
Financials of Glaxosmithkline Pharmaceuticals Ltd
Profit & Loss
Annual income statement trend
| Mar 2015 15m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,305 | 2,838 | 2,908 | 2,871 | 3,128 | 3,224 | 2,926 | 3,278 | 3,252 | 3,454 | 3,749 | 3,822 |
| Expenses + | 2,672 | 2,360 | 2,489 | 2,363 | 2,527 | 2,567 | 2,327 | 2,516 | 2,447 | 2,545 | 2,570 | 2,512 |
| Operating Profit | 633 | 478 | 420 | 508 | 601 | 657 | 598 | 762 | 804 | 909 | 1,179 | 1,309 |
| OPM % | 19% | 17% | 14% | 18% | 19% | 20% | 20% | 23% | 25% | 26% | 31% | 34% |
| Other Income + | 149 | 125 | 119 | 70 | 131 | -262 | 9 | 1,401 | 103 | -21 | 149 | 166 |
| Interest | 0 | 0 | 0 | 0 | 1 | 6 | 4 | 2 | 2 | 2 | 1 | 3 |
| Depreciation | 25 | 25 | 27 | 38 | 49 | 83 | 79 | 68 | 66 | 70 | 67 | 66 |
| Profit before tax | 756 | 578 | 511 | 540 | 683 | 306 | 525 | 2,093 | 839 | 816 | 1,260 | 1,406 |
| Tax % | 37% | 35% | 34% | 35% | 35% | 70% | 32% | 19% | 27% | 28% | 26% | 26% |
| Net Profit + | 476 | 376 | 337 | 351 | 445 | 93 | 358 | 1,695 | 611 | 590 | 928 | 1,036 |
| EPS in Rs | 28.12 | 22.20 | 19.88 | 20.70 | 26.29 | 5.50 | 21.14 | 100.04 | 36.05 | 34.83 | 54.75 | 61.15 |
| Dividend Payout % | 111% | 113% | 75% | 85% | 76% | 727% | 142% | 90% | 89% | 92% | 99% | 93% |
Financials of Glaxosmithkline Pharmaceuticals Ltd
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
| Reserves | 1,744 | 2,099 | 1,922 | 1,973 | 1,970 | 1,651 | 1,309 | 2,494 | 1,572 | 1,608 | 1,782 | 2,098 |
| Borrowings + | 3 | 2 | 2 | 1 | 1 | 0 | 35 | 20 | 16 | 19 | 10 | 33 |
| Other Liabilities + | 1,384 | 869 | 995 | 1,889 | 1,771 | 1,315 | 1,602 | 1,950 | 1,570 | 1,760 | 2,147 | 2,023 |
| Total Liabilities | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 4,324 |
| Fixed Assets + | 123 | 204 | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 321 | 284 | 281 |
| CWIP | 115 | 268 | 605 | 923 | 1,003 | 120 | 13 | 30 | 20 | 14 | 14 | 33 |
| Investments | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 366 | 518 | 813 | 1,118 | 1,392 |
| Other Assets + | 2,977 | 2,577 | 2,140 | 2,700 | 2,477 | 2,257 | 2,715 | 3,907 | 2,458 | 2,408 | 2,692 | 2,618 |
| Total Assets | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 4,324 |
Financials of Glaxosmithkline Pharmaceuticals Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 338 | 139 | 234 | 473 | 409 | 490 | 578 | 811 | 484 | 582 | 1,290 | 903 |
| Cash from Investing Activity + | 180 | 499 | 301 | -104 | -153 | -57 | 418 | -406 | 808 | 9 | -46 | 397 |
| Cash from Financing Activity + | -497 | -638 | -511 | -307 | -358 | -428 | -696 | -524 | -1,543 | -562 | -769 | -737 |
| Net Cash Flow | 21 | -0 | 24 | 62 | -102 | 6 | 300 | -119 | -251 | 29 | 475 | 563 |
| Free Cash Flow | 175 | -69 | -24 | 639 | 166 | 336 | 536 | 2,371 | 451 | 573 | 1,273 | 849 |
| CFO/OP | 93% | 72% | 94% | 133% | 101% | 103% | 121% | 122% | 93% | 92% | 116% | 93% |
Financials of Glaxosmithkline Pharmaceuticals Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 11 | 16 | 21 | 19 | 14 | 11 | 27 | 23 | 22 | 23 | 28 | 26 |
| Inventory Days | 91 | 156 | 111 | 147 | 131 | 135 | 159 | 144 | 131 | 144 | 126 | 124 |
| Days Payable | 74 | 97 | 73 | 149 | 109 | 100 | 135 | 156 | 122 | 171 | 186 | 154 |
| Cash Conversion Cycle | 27 | 75 | 60 | 17 | 36 | 46 | 50 | 11 | 31 | -4 | -31 | -4 |
| Working Capital Days | -48 | 26 | 7 | -90 | -72 | -38 | -39 | -94 | -57 | -64 | -99 | 42 |
| ROCE % | 42% | 29% | 22% | 26% | 31% | 33% | 38% | 37% | 36% | 51% | 63% | 65% |
Guidance history
How Glaxosmithkline Pharmaceuticals Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Flat | Planned | — | — |
| Q4 FY26 call → | 10–20% | Flat | Planned | — | — |
| Q3 FY26 call → | 10–20% | Flat | Planned | — | — |
| Q2 FY26 call → | 0–10% | Flat | — | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
30 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −4.8% | 55% |
| Last 6 months | +7.6% | 64% |
| Last 3 months | −3.7% | 57% |
The price is 27.3% below its all-time high of ₹3,457.7 (27 Jun 2025). Stocks more than 20% below their peak have their score halved, so 59 became 30.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Glaxosmithkline Pharmaceuticals Ltd: 0.4 × 55 + 0.4 × 64 + 0.2 × 57 = 59, halved to 30 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Glaxosmithkline Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY